Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...
VIENNA, Va., February 20, 2025--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial. VIENNA, Va., February 18, 2025--CEL-SCI reports fiscal Q1 2025 financial results: Multikine shows ...
Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval.
--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it is in the final stages for the launch of its 212-patient Confirmatory Registration Study for Multikine* (Leukocyte ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...